Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study of seven randomized clinical trials, JAK inhibitors were associated with improved hair regrowth outcomes in alopecia areata patients compared to placebo, with oral administration being more effective than external application, though longer trials are needed to confirm safety and effectiveness.

Upadacitinib effectively treats pyoderma gangrenosum.

This review discusses the potential of JAK inhibitors for treating alopecia areata and reports case study evidence of their effectiveness, but formal clinical trials are needed for more definitive conclusions.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

This source discusses the potential of topical JAK inhibitors, like tofacitinib, as effective treatments for autoimmune skin diseases, emphasizing their superior safety profile and minimal adverse effects compared to conventional systemic therapies.

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

This case study reports that a 15-year-old male with multiple autoimmune conditions showed significant improvement in skin and gastrointestinal symptoms, along with hair regrowth, after 16 weeks of treatment with the JAK-1 inhibitor upadacitinib, demonstrating its potential in managing complex autoimmune disorders.

This review examines the JAK/STAT signaling pathway's significance in inflammatory skin diseases and evaluates the efficacy and safety of oral and topical JAK inhibitors for treating vitiligo and alopecia areata. Results are not reported in this study.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

This study reported that tofacitinib may be a promising treatment for alopecia areata in adolescents, showing significant hair regrowth with mild adverse effects in a retrospective review.

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.

In this study, baricitinib improved the resolution of arthritis or rash in patients with systemic lupus erythematosus, but outcomes for skin involvement like alopecia were not reported.

JAK inhibitors may reduce depression risk in alopecia areata patients.

This review discusses the role of JAK inhibitors in treating alopecia areata by targeting the JAK/STAT pathway and highlights the promising results but also ongoing challenges such as relapse risk and side effects.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This case report details the successful use of oral tofacitinib for six months, which led to significant hair regrowth in an adult male Indian patient with extensive and refractory alopecia areata, highlighting tofacitinib's potential in managing resistant cases within this population.

This case report highlights the successful use of tofacitinib in a 12-year-old patient with Crohn’s disease who developed alopecia areata following infliximab treatment, showing significant hair regrowth and complete resolution of alopecia within eight months while maintaining remission of Crohn’s symptoms.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

In this case study, a transition to the MEK inhibitor trametinib successfully stabilized disease and reduced toxicity in a patient with refractory kaposiform lymphangiomatosis after prolonged sirolimus and steroid treatment.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

In this report, a 35-year-old female with palmoplantar pustulosis undergoing secukinumab treatment developed alopecia areata, a rare side effect attributed to paradoxical reactions with IL-17 inhibitors; switching to tofacitinib improved both conditions.

This study investigated the impact of the JAK inhibitor ruxolitinib on APS-1 patients, reporting that treatment decreased excessive T-cell-derived interferon-γ, normalized inflammatory markers, and led to remission of several autoimmune symptoms without serious adverse effects.

Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.

In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.

In this study, oral JAK inhibitors were found to be significantly more effective than placebo in promoting hair regrowth among adults and adolescents with moderate-to-severe alopecia areata, although they were associated with an increased risk of adverse events.

In this study using C3H/HeJ mice, a single subcutaneous injection of the fusion protein PTH-CBD increased anagen hair follicle counts and promoted hair regrowth comparably to daily oral ruxolitinib, potentially by enhancing beta-catenin production and stimulating anagen transition.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Tofacitinib may effectively treat folliculitis decalvans.